- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Interventions
- Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection
- Drug · Other
- Lead sponsor
- DiaMedica Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 728 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 36
- States / cities
- Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- IMVT-1402, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
- Conditions
- Early Alzheimer's Disease
- Interventions
- Lecanemab IV, Placebo, Lecanemab SC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 112
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- Efavaleukin alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Santa Maria, California • Kissimmee, Florida • Kansas City, Kansas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more
- Conditions
- Uveitis
- Interventions
- Izokibep, Placebo
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Hereditary Angioedema
- Interventions
- CSL312, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Interventions
- LY2127399, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Hepatitis B
- Interventions
- Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Crohn's Disease
- Interventions
- IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 87
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- LY3471851, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
- Conditions
- Primary Amenorrhea With Hypogonadotropic Hypogonadism
- Interventions
- Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
- Conditions
- HIV
- Interventions
- PRO 140, Placebo, Optimized Background Regimen
- Drug
- Lead sponsor
- CytoDyn, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 34
- States / cities
- Fountain Valley, California • Long Beach, California • Los Angeles, California + 24 more
- Conditions
- Chronic Kidney Disease Associated Moderate to Severe Pruritus
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 47
- States / cities
- Bakersfield, California • Glendale, California • La Palma, California + 40 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 56
- States / cities
- Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
- Interventions
- KPL-716, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
- Conditions
- Dyslipidemias
- Interventions
- LY3561774, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Cypress, California • Long Beach, California • South Miami, Florida + 2 more
- Conditions
- Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
- Interventions
- Litifilimab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 62
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Ulcerative Colitis
- Interventions
- Amg 181
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Glendale, California • Danbury, Connecticut • Plymouth, Minnesota + 1 more
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Interventions
- Maridebart Cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 45 Years to 99 Years
- Enrollment
- 12,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 140
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo matching with BMS-945429, BMS-945429
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Guselkumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 204
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more